M.Needham,F.L.Mastaglia/NeuromuscularDisorders24(2014)4–157
statins,undergoesalternativesplicingofexon13whichencodesthebindingdomainofstatinstotheenzyme.Theresultingisoform(HMGCRv)showsalteredenzymeactivityandsensitivitytostatinscomparedtotheclassicalisoform.Thistranslatesintointer-individualdi erencesintheresponsetothesedrugs.Manyofthesepolymorphismsstillrequirevalidation,ascon ictingresultsexistpossiblyduetodi erencesinthepopulations,di erentcombinationsoftheDNAvariations,thestatinusedanddi eringoutcomes,asdiscussedbyHirschhorn[87]andWilke[76].3.2.Geneticmarkersforstatinmyotoxicity
Thusfarthesearchforgeneticpredispositionforstatin-inducedmyopathyhaslargelybeendoneonacandidategeneapproach,investigatinggenesencodingproteinsinvolvedinstatintransportandmetabolism,aswellasthosehypothesizedtobeimportantinthepathogenesisofstatin-inducedmyopathy,(Fig.1).Althoughgeneticdeterminantsofstatinmyopathyhavenotyetbeenfullyestablished,somegeneticmarkershavebeenidenti edaspossiblyincreasingtheriskofstatintoxicity,(Table2).HoweveronlypolymorphismsintheSLCO1B1gene,whichencodestheproteinresponsibleforhepaticuptakeofstatins,andtheCOQ2gene,importantinthesynthesisofCoenzymeQ10,havebeenvalidatedasbeingstronglyassociatedwithstatin-inducedmyopathy[1,88].RecentlytheHLAclassIIallele,DRB1*11:01wasidenti edasastronggeneticriskfactorforthedevelopmentofonespeci cstatin-myopathy,theanti-HMGCR-associatednecrotizingimmunemyopathy[89].Geneticmutationscausingmetabolicandothermyopathieshavealsobeeninvestigatedfortheirpossibleassociationincausingstatin-inducedmyopathies[90].3.3.Geneticmodi ersintheHMG-CoAreductasepharmacokineticpathway
Drugtransporterproteinsandthemetabolizingenzymesarethetwomajorbiologicalfactorsthatdeterminethepharmacokineticsofdrugs.Asthetoxicityofstatinsappearstoberelatedtothedoseused,itisreasonabletoconsiderthatindividualdi erencesinpharmacokineticsmaypredisposetostatinmyopathies.Belowthestudiesinvestigatinggeneticvariationsinstatindrugtransporters,pharmacokineticpathwaysarereviewed.3.3.1.Geneticvariationinstatindrugtransporters
Statinsarebothlipophilic(e.g.,simvastatin,lovastatin,atorvastatin)andhydrophilic(e.g.,rosuvastatin, uvastatin,pravastatin).Hydrophilicstatinsrequirecarrierproteinsforabsorptionandtransportfromtheintestineintothebloodstream,aswellasfromthebloodintohepatocytesformetabolism.Theorganicaniontransportingpolypeptide(OATP1B1)isthetransporterproteinforhydrophilicstatinsintohepatocytesregulating
liveruptake,andisencodedbytheSLCO1B1gene,(reviewedin[91,92]).Polymorphismsinthisgeneareassociatedwithreducedhepaticuptakeofmanystatins,increasedplasmalevelsandthereforepotentiallyahigherriskofstatin-associatedmyopathy[93–99].
However,inthestudyofthee ectivenessofadditionalreductionsincholesterolandhomocysteine(SEARCH),onlyasinglenucleotidepolymorphism(rs4363657),whichtagsaknownnon-synonymousvariant(Val174Ala)inintron11wasidenti edtobeassociatedwithmyopathyinpatientstakingsimvastatin.Inthisstudypopulation,patientshomozygousforthisriskallelehadan18.6%chanceofdevelopingmuscletoxicityover5yearscomparedwiththe0.63%riskinthegroupthatwerehomozygousforthelow-riskallele[97].ThisatriskallelewasalsolinkedtodevelopingmyalgiawithoutCKrise,andhasbeenvalidatedintwofurtherstudies[94,98].Thiscon rmsthatgeneticvariantsincreasingserumdrugconcentrationarelinkedtomusclesidee ects,butthepredictivevalueandclinicalutilityofthismarkerhasyettobefullyde nedwithallstatins.HowevergiventhehighqualityofevidencelinkingmyopathytoSLCO1B1genotypeinpatientsonsimvastatin,analgorithmhasrecentlybeenproposed[100]advisingtheuseofthegenotypeincombinationwiththerecentFDAguidelines[101],toguidesimvastatindosage.
Inaddition,changesinothercarriersa ectingtheeliminationofstatinsfromcellsmaybeimportant,suchasthebreastcancerresistantprotein(BRCP)encodedbytheABCG2geneandtheP-glycoprotein,multi-drugresistanceprotein(MRP2)encodedbytheABCB1gene.ThisP-glycoproteinisanATP-dependente uxpumpforawidevarietyoflipophiliccompoundsincludingsimvastatin,anditisusedtohelpcontroltheintracellularconcentrationoftoxicsubstances.Thereforevariationsinthesepumpscouldcausedi erencesintheire uxactivity,increasingsystemicexposuretovariousstatinsandpotentiallyincreasingtheirtoxicityincertainindividuals[93].Fiegenbaumetal.[102]investigatedtherelationshipbetweenpolymorphismsinABCB1,CYP3A4andCYP3A5genesandthee cacyandsafetyofsimvastatin.NopolymorphismsinCYP3A5wereassociatedwithmyalgias,buttheyfoundreducedallelefrequency(1236T,2677non-Gand3435T)intheABCB1geneinpatientsinwhommyalgiadeveloped,ascomparedwiththegroupwhodidnotsu eranadversereaction(P<0.05)ThissuggestedthatABCB1variantsmayplayaroleinthedevelopmentofstatin-associatedmyalgia.Kajinami[103]hadpreviouslyreportedthattheC3435Tpolymorphismwasassociatedwithasigni cantlysmallerreductioninlow-densitylipoprotein,andalargerincreaseinhigh-densitylipoproteinrelativetovariantallelecarrierstreatedwithatorvastatin.
3.3.2.GeneticvariationintheCYPenzymesystem
Themajorityofstatinsarehighlyproteinboundandhavealowsystemicbioavailabilityduetoextensive rst
热门文档